Record-Breaking Price Movement
On 13 August 2026, Fredun Pharmaceuticals Ltd’s stock surged to an intraday high of Rs.1464.95, representing a 5.11% increase on the day and outperforming its sector by 4.47%. The stock closed with a day change of 4.75%, continuing its upward momentum. This new peak surpasses the previous 52-week high of Rs.1401.00 by 4.21%, underscoring the stock’s robust bullish trend.
The stock has been on a consistent upward trajectory, gaining for three consecutive days and delivering a 19.46% return during this period. It is currently trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – which further confirms the strength of the ongoing rally.
Outperformance Against Benchmarks
Fredun Pharmaceuticals Ltd has demonstrated exceptional performance relative to the broader market. Over the last one day, the stock gained 4.61% while the Sensex declined by 0.23%. Over one week, the stock rose 19.33% compared to a 1.48% fall in the Sensex. The one-month return stands at an impressive 58.84%, dwarfing the Sensex’s modest 0.22% gain.
Longer-term figures are even more striking. The stock has delivered a 319.17% return over the past year, vastly outperforming the Sensex’s 3.42% decline. Year-to-date, Fredun Pharmaceuticals Ltd has gained 177.13%, while the Sensex has fallen 8.72%. Over three years, the stock’s return of 332.03% far exceeds the Sensex’s 19.08%, and over five years, it has surged 975.62% compared to the Sensex’s 40.31%.
Strong Financial Growth Underpinning the Rally
The company’s impressive stock performance is supported by solid financial fundamentals. Fredun Pharmaceuticals Ltd has achieved a healthy compound annual growth rate (CAGR) in net sales of 34.99% over five years, alongside an operating profit growth rate of 62.66%. The latest quarterly results for June 2026 highlight a net profit growth of 94.53%, reflecting outstanding operational efficiency and profitability.
Key financial metrics reached new highs in the recent quarter, including net sales at Rs.228.25 crores, operating cash flow on an annual basis at Rs.16.44 crores, and an operating profit to interest coverage ratio of 3.80 times. The company has also maintained positive results for nine consecutive quarters, signalling consistent performance.
Valuation and Quality Assessment
Fredun Pharmaceuticals Ltd is classified as a micro-cap company with a Mojo Score of 77.0 and a current Mojo Grade of Buy, recently adjusted from Strong Buy on 12 August 2026. The valuation multiples as of 13 August 2026 include a price-to-earnings (P/E) ratio of 53x, price-to-book value (P/BV) of 8.27x, and an enterprise value to capital employed (EV/CE) ratio of 5.65x. The PEG ratio stands at 0.83x, indicating a valuation that is reasonable relative to earnings growth.
Dividend metrics show a modest yield of 0.03% with a latest dividend of Rs.0.233 per share and a payout ratio of 1.15%, reflecting a conservative dividend policy aligned with reinvestment for growth.
Quality assessments rate the company as average overall, with excellent growth but below-average capital structure and moderate leverage. The return on capital employed (ROCE) is 19.9%, which is solid, though the valuation is considered on the higher side compared to peers’ historical averages.
Technical Indicators Confirm Bullish Momentum
The technical trend for Fredun Pharmaceuticals Ltd remains bullish, with the trend having shifted from mildly bullish on 9 April 2026 at a price of Rs.611.58. Weekly and monthly technical indicators such as MACD, Bollinger Bands, and KST are all signalling bullish momentum. The stock’s immediate support level is Rs.338.73, the 52-week low, while the previous major resistance levels at Rs.683.62 (200 DMA), Rs.811.72 (100 DMA), and Rs.1047.62 (20 DMA) have been decisively surpassed.
Delivery volumes have also increased significantly, with a 1-month delivery change of 257.25% and a 1-day delivery change of 25.39% compared to the 5-day average, indicating strong participation in the recent rally.
Summary of Financial Trends
The short-term financial trend as of June 2026 is outstanding, with several key performance indicators reaching record levels. Operating cash flow, net sales, operating profit to interest coverage, profit before depreciation and interest tax (Pbdit), and profit after tax (PAT) have all hit new highs. The company’s debt-equity ratio is at a low 0.80 times, reflecting prudent financial management despite a 26.42% increase in interest expenses over the last six months.
This combination of strong earnings growth, improving cash flows, and manageable leverage has supported the stock’s sustained upward movement and all-time high price.
Conclusion
Fredun Pharmaceuticals Ltd’s stock reaching an all-time high of Rs.1464.95 on 13 August 2026 marks a significant achievement reflecting the company’s robust financial health and consistent growth trajectory. The stock’s outperformance against major indices and sector peers, combined with strong quarterly results and positive technical signals, highlights a well-established upward trend. While valuation metrics suggest a premium, the company’s growth fundamentals and quality indicators provide a comprehensive picture of its market standing at this milestone.
